Results 81 to 90 of about 6,404 (193)

Trained Immunity Generated by the Recombinant Zoster Vaccine

Abstract Trained immunity may play a role in vaccine-induced protection against infections. We showed that the highly efficacious recombinant VZV-gE zoster vaccine (RZV) generated trained immunity in monocytes, natural killer (NK) cells, and dendritic cells (DCs) and that the less efficacious live zoster vaccine did ...
Adriana Weinberg, Michael Johnson, Megan Crotteau, Debashis Ghosh, Thao Vu, Myron J Levin   +5 more
openaire   +2 more sources

Supplementary Material. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older [PDF]

, 2018
Supplementary Material Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and ...
Curra, Desmond, Heineman, Thomas, McElhaney, Janet, Díez Domingo, Javier, Matthews, Sean, Oostvogel, Lidia, McNeil, Shelly   +6 more
core  

Comparative risk of Guillain–Barré syndrome recombinant and live zoster vaccines: a pharmacovigilance study using VAERS and EudraVigilance database

Immunological Medicine
This study aimed to compare the risk signals of Guillain–Barré syndrome (GBS) associated with recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) to improve understanding of herpes zoster vaccine safety.
Yinpeng Xu, Fang Li, Li Huang, Dan Mei, Pengqiang Du   +4 more
doaj   +1 more source

Varicella and Herpes zoster vaccines: from live attenuated vaccines to genetically engineered products

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. Varicella zoster virus remains a serious threat to public health and is a sig­nificant burden on the health system due to treatment costs. Vaccination coverage against varicella zoster (VZ) and herpes zoster (HZ) remains low for a number of
A. V. Zotova, O. A. Svitich
doaj   +1 more source

AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults

The recombinant zoster vaccine (RZV), which uses the AS01 adjuvant system, confers more than 90 % efficacy in older adults against herpes zoster. While most older adults have been exposed to chickenpox, it remains unclear why a two-dose schedule is ...
Cheung, Yin Bun, Tham, Christine Y.L., Low, Jenny G., Yee, Jia Xin, Chan, Candice C.Y., Ooi, Justin S.G., Chew, Valerie S.Y., Ooi, Eng Eong, Chan, Kuan Rong, Ong, Eugenia Z., Koh, Clara W.T.   +10 more
core   +1 more source

A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold.

PLoS Pathogens
Varicella-zoster virus (VZV), the cause of shingles, remains a significant health issue worldwide, particularly among aging populations. The recombinant zoster vaccine (Shingrix, RZV) is the only approved vaccine in many countries and has demonstrated ...
Wenhui Xue, Hong Wang, Yarong Zeng, Sibo Zhang, Lingyan Cui, Hongjing Liu, Hai Li, Minqing Hong, Huizheng Zhang, Yuyun Zhang, Jinjin Li, Zhenqin Chen, Qingbing Zheng, Hai Yu, Rui Zhu, Lizhi Zhou, Ying Gu, Tingting Li, Ningshao Xia, Shaowei Li   +19 more
doaj   +1 more source

Immune responses to zoster vaccines

Human Vaccines & Immunotherapeutics, 2019
There are two licensed herpes zoster vaccines. One is a live vaccine (ZVL) based on an attenuated varicella-zoster virus (VZV). The other is a recombinant vaccine (RZV) based on the VZV glycoprotein E (gE) combined with AS01B, a multicomponent adjuvant ...
Myron J Levin, Adriana Weinberg
doaj   +1 more source

Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) [PDF]

Zoster-2-Shimabukuro-508 ...

core  

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source